The study aimed to evaluate the efficacy and safety of HD-MT with or without IT-MT and WBRT for PCNSL. The results showed no significant difference in efficacy between HD-MT alone or with IT-MT plus radiotherapy, with manageable side effects. Primary central nervous system lymphoma (PCNSL) is a rare and aggressive type of lymphoma. […]
Spinal Chondrosarcoma Subtypes: Prognosis and Treatment Analysis
The study aimed to analyze differences in clinical, molecular, therapeutic, and prognostic factors among spinal chondrosarcoma subtypes. The results showed upregulated p53/MDM2 pathway in MCS and DCS, with radical resection crucial for spinal chondrosarcoma. Spinal chondrosarcoma is more invasive and has a worse prognosis than extremity chondrosarcoma. Prognosis and treatment vary among chondrosarcoma […]
USF1: A Potential Prognostic Marker in AML
The study aimed to evaluate the expression of USF1 in patients with AML and determine its clinical and prognostic significance. The results showed that high USF1 expression was associated with poor prognosis and reduced survival in patients with AML. Acute myeloid leukaemia (AML) is a heterogeneous haematologic malignancy with varying prognoses. Identifying reliable […]
Efficacy of Axitinib + Avelumab in Pretreated Advanced GIST
The AXAGIST phase 2 trial aimed to investigate the synergy of axitinib and avelumab in advanced GIST after standard therapy failure. The primary endpoint was to determine PFS. Researchers noted significant efficacy and long-term benefit from the axitinib-avelumab combination in pretreated GIST. The development of tyrosine kinase inhibitors (TKIs) has significantly advanced the […]
TAR-200 + CET vs CET Alone in Patients With MIBC: SR-4 Interim
The SunRISe-4 phase 2 trial aimed to assess the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab vs cetrelimab alone in patients with MIBC. The primary endpoint was to determine pCR, and the secondary endpoints were pOR rate & safety. Researchers noticed a favorable safety profile and compelling efficacy data; further investigation is […]
Efficacy of Low vs Standard Pembrolizumab in NSCLC
The DEDICATION-1 phase 3 trial aimed to investigate if reduced-dose pembrolizumab is as effective as standard dosing in stage IV NSCLC. Researchers noticed a 3.2% difference in one-year survival, meeting the criteria to continue the study. Immune checkpoint inhibitors have demonstrated improved overall survival (OS) for patients with metastatic non-small cell lung carcinoma […]
MOST RECENT
177Lu-PNT2002 Enhances ORR and HRQoL in PSMA+ mCRPC
The study aimed to investigate 177Lu-PNT2002’s efficacy in PSMA-positive in patienst with mCRPC after ARPI failure. The primary endpoint was to determine rPFS and BICR. Researchers noted that 177Lu-PNT2002 improved outcomes in PSMA-positive mCRPC compared to ARPI. The metastatic castration-resistant prostate cancer (mCRPC) is a life-threatening condition with significant unmet needs. 177Lu-PNT2002 is […]
Belomethason Inhalation Reduces RIP in NSCLC During RT
The phase 2 trial aimed to investigate belomethason inhalation’s impact on reducing RIP in patients with NSCLC. The primary endpoint is RIP. Researchers noticed inhaled corticosteroids cut RIP in NSCLC, warranting phase III validation. Thoracic radiotherapy (RT) is crucial in the comprehensive treatment of non-small cell lung cancer (NSCLC). However, radiation-induced lung injury […]
NKT2152 Shows Promising Efficacy in Pretreated Advanced RCC
The phase 1 and 2 trial aimed to investigate the safety, pharmacokinetics, pharmacodynamics, and efficacy of NKT2152 in patients with accRCC. NKT2152 showed strong anti-tumor activity in patients with heavily pretreated accRCC, with a consistent safety profile. NKT2152, a novel oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, is being developed for treating advanced clear […]
Tivozanib vs Combo Therapy in Advanced RCC Outcomes: TiNivo-2
The TiNivo-2 phase 3 trial aimed to evaluate whether tivozanib + nivolumab improves outcomes vs. tivozanib alone in patients with RCC after ICI. The primary endpoint was PFS. The study concluded that ICI rechallenge didn’t improve outcomes, supporting tivozanib monotherapy as second-line treatment. Tivozanib, a selective vascular endothelial growth factor receptor (VEGFR) tyrosine […]
Advertisement
MOST RECENT
Popular With Peers
SKB264 + KL-A167 Shows Promise in NSCLC: OptiTROP-Lung01
The study aimed to assess the efficacy and safety of combining SKB264 with KL-A167 in patients with advanced NSCLC. Researchers observed that SKB264 + KL-A167 demonstrated promising efficacy and safety; further investigation is ongoing. Sacituzumab Tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase […]
Efficacy of Fulzerasib/Cetuximab in KRAS G12C NSCLC
The phase 1 & 2 trial aimed to investigate the efficacy and safety of combining fulzerasib, with cetuximab as front-line treatment for patients with NSCLC. The primary objective was to evaluate fulzerasib with cetuximab in untreated advanced NSCLC with KRAS G12C mutation. Researchers noticed promising efficacy and safety of fulzerasib + cetuximab; further […]
TN+ SPA or RIB Therapies: Safe & Tolerated
The phase I trial aimed to assess TN’s safety and efficacy combined with SPA or RIB in advanced solid tumor patients. The results demonstrated that TN combined with SPA or RIB was well-tolerated at recommended doses, with safety profiles consistent with individual agents. Omar Saavedra Santa Gadea and the team spearheaded the study […]
VenDd Elicits Durable MRD Negativity in Myeloma
The interventional phase 2 trial aimed to compare MRD in VenDd vs. DVd RRMM. The results demonstrated that VenDd was superior MRD clearance and extended PFS in t(11;14)-positive RRMM compared to DVd. Multiple myeloma shows hematologic malignancies that involve abnormal cell proliferation in the bone marrow—the combination of venetoclax (Ven), a potent BCL-2 […]
Combined Efficacy of Tucatinib and Trastuzumab for HER2-Positive MBTC
The phase II trial aimed to evaluate the combined efficacy and safety of TUC and Tras in HER2-altered solid tumor pts. The primary endpoint was cORR. Secondary endpoints include OS, DCR, DOR, PFS, and safety. The study found that combined therapy was well-tolerated and showed promising antitumor activity in pts. Biliary tract cancer […]
Amivantamab Shows Efficacy In Pts With Advanced NSCLC
The phase 1 CHRYSALIS study evaluated amivantamab (ami) for treating advanced non-small cell lung cancer with EGFR Ex20ins mutations. Patients who had experienced disease progression on platinum-based chemotherapy were enrolled in the study. The study demonstrated the effectiveness of amivantamab in treating advanced NSCLC with EGFR Ex20ins mutations across diverse patient groups and […]
PSCA-Targeted CAR T Cells Show Promise in mCRPC Patients
The phase I trial aimed to evaluate the safety and efficacy of PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in patients with mCRPC. CAR T cells were manufactured and infused into patients with disease progression after at least 1 androgen receptor-targeted therapy. The study found that PSCA-CAR T cells can potentially treat mCRPC, but […]
CheckMate 214 Study: Clinical Efficacy of NIVO+IPI in sRCC Patients
Phase 3 of CheckMate 214 trial was conducted to study the long-term efficacy and suitability of NIVO+IPI as a 1L treatment for patients with Untreated Advanced or Metastatic Renal Cell Carcinoma with Sarcomatoid features. 139 patients were randomized in an open-label trial to compare the NIVO+IPI combination with SUN monotherapy, where NIVO+IPI proved […]
ctDNA Testing in mCRPC Patients with HRR Gene Alterations
The phase 3 PROfound study included patients with mCRPC whose plasma samples were retrospectively sequenced using circulating tumor DNA (ctDNA) Next-Generation Sequencing (NGS) to test for BRCA/ATM alterations. The efficacy of Olaparib was consistent, irrespective of the method used to identify the BRCA/ATM alterations. The study demonstrated that ctDNA NGS might be used […]
Enrolling Trials
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
SELECT ONCOLOGY JOURNAL ARTICLES
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer
Background Major histocompatibility complex class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their …
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …